US and EU approval for St Jude's non-rechargeable neurostimulator
This article was originally published in Clinica
Executive Summary
St Jude Medical has launched its EonC neurostimulator in the US following FDA premarket approval (PMA) for the treatment of chronic pain. The St Paul, Minnesota firm also CE marked the product for sale in Europe, and will launch it there next week. EonC delivers mild electrical pulses to the spinal cord, interrupting or masking pain signals. It is non-rechargeable, unlike St Jude's Eon and Eon Mini devices, which can be charged in a similar way to a mobile phone. St Jude said that EonC was designed for patients who do not want to be burdened with recharging, and claims it has the greatest battery capacity of any primary cell neurostimulator.